Whalesbook
### Earnings Lag Expectations Amid Margin Compression
Cipla reported a stark contrast between revenue and profitability in its third quarter of fiscal year 2026. While revenue held largely flat at ₹7,074 crore year-on-year, net profit experienced a significant 57% decline, falling to ₹675 crore. This performance missed analyst consensus estimates, with revenue, EBITDA, and PAT falling short [cite: Original News Snippet]. The company's EBITDA margin compressed considerably, dropping to 17.7% from 28.1% in the prior year's comparable quarter. This downturn was exacerbated by a 37% year-on-year increase in R&D expenses, reaching ₹490 crore, which constituted 7% of sales.
### Key Headwinds: Supply Chain Woes and Product Contributions
Several factors contributed to the profitability squeeze. A primary concern is the disruption in the supply of Lanreotide, a key product in the US market. Production at its European contract manufacturer, Pharmathen, was halted following nine observations from a USFDA inspection, with resupply anticipated in the first half of FY27. This issue directly impacted the North America business, leading to a 22% revenue decline. Additionally, the contribution from gRevlimid, a previously significant revenue driver, has diminished. The company also incurred a one-time exceptional expense of approximately ₹276 crore related to the implementation of new labor codes, further pressuring the bottom line.
### Nuvama Downgrades, Citing Limited Upside
In response to the weaker-than-expected quarterly results and ongoing challenges, brokerage Nuvama Institutional Equities has downgraded Cipla to a 'Reduce' rating. Nuvama has also lowered its target price for the stock to ₹1,280, implying a potential downside of approximately 2.7% [cite: Original News Snippet]. The brokerage cited earnings concerns, significant margin pressure, and the impact of supply disruptions as key reasons for its cautious stance. Nuvama has revised its earnings per share estimates downward, cutting FY26 and FY27 projections by approximately 10% and 5%, respectively [cite: Original News Snippet]. At current valuations, trading at roughly 21-24 times forward earnings, Nuvama believes there is limited room for significant upside unless earnings improve markedly [cite: Original News Snippet].
### Future Outlook and Pipeline Potential
Despite near-term challenges, Cipla's medium-term outlook is supported by a robust product pipeline, particularly in the United States. The company plans to launch eight new products within the next 6 to 18 months, including four respiratory assets, such as generic versions of Advair and Symbicort, and four peptide products, including generic Victoza. The acquisition of perpetual rights to the Galvus brand for type 2 diabetes treatment, for approximately ₹1,107 crore, is also expected to contribute to future earnings. However, visibility on margin recovery and the full impact of these launches, along with the Lanreotide supply situation and the status of the Indore facility, remain key areas for investor scrutiny. The Indian pharmaceutical sector as a whole is projected to see moderate growth, with domestic markets remaining strong while the US market faces moderation and increased competition.